Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cingulate Inc ( (CING) ) has issued an announcement.
On August 14, 2025, Cingulate Inc. appointed John A. Roberts as Executive Chairman and placed CEO Shane Schaffer on administrative leave, with changes to their compensation structures. Additionally, Laurie Myers’ employment ended on August 7, 2025, and she signed a Separation Agreement with Cingulate Therapeutics LLC on August 28, 2025, which includes confidentiality and non-competition clauses, along with a separation pay and other terms.
The most recent analyst rating on (CING) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 127,279
Technical Sentiment Signal: Sell
Current Market Cap: $23.27M
For detailed information about CING stock, go to TipRanks’ Stock Analysis page.